Construct validation of the hospital anxiety and depression scale with clinical populations

Johnston, Marie; Pollard, Beth; Hennessey, Paula E.

doi:10.1016/s0022-3999(00)00102-1

Cited by 308 publications

(212 citation statements)

References 10 publications

Supporting

Mentioning

202

Contrasting

Unclassified

Order By: Relevance

“…This cutoff score was reported by Ibbotson et al (1994) to be the best for identifying patients likely to have an interview based diagnosis of depressive or anxiety disorder. The reliability, validity and factor structure of the HADS has been established in a variety of clinical populations (Moorey et al, 1991;Johnston et al, 2000;Mykletun et al, 2001;Smith et al, 2002) and validated in this population of cancer patients. We found that a cutoff of 15 or above on the total HADS score gave a (Walker et al, in press).…”

Section: Methodsmentioning

confidence: 99%

Emotional distress in cancer patients: the Edinburgh Cancer Centre symptom study

et al. 2007

View full text Add to dashboard Cite

To: (1) estimate the prevalence of clinically significant emotional distress in patients attending a cancer outpatient department and (2) determine the associations between distress and demographic and clinical variables, we conducted a survey of outpatients attending selected clinics of a regional cancer centre in Edinburgh, UK. Patients completed the Hospital Anxiety and Depression Scale (HADS) on touch-screen computers and the scores were linked to clinical variables on the hospital database. Nearly one quarter of the cancer outpatients 674 out of 3071 (22%; 95% confidence interval (CI) 20 -23%) met our criterion for clinically significant emotional distress (total HADS score 15 or more). Univariate analysis identified the following statistically significant associations: age o65, female gender, cancer type and extent of disease. Multivariate analysis indicated that age o65 (odds ratio 1.41; 95% CI 1.18 -1.69), female gender (odds ratio 1.58; 95% CI 1.31 -1.92) and active disease (odds ratio 1.72; 95% CI 1.43 -2.05) but not cancer diagnosis, were the independent predictors of clinically significant emotional distress. Services to treat distress in cancer patients should be organised to target patients by characteristics other than their cancer diagnosis.

show abstract

Section: Methodsmentioning

confidence: 99%

Emotional distress in cancer patients: the Edinburgh Cancer Centre symptom study

et al. 2007

View full text Add to dashboard Cite

show abstract

“…This 14-item questionnaire has been validated in a number of clinical situations and has been widely used in patients with cancer. 49,50 Global Symptom Evaluation. Patients were asked about their fatigue (worse, about the same, or better) after starting study medication.…”

Section: Outcome Measuresmentioning

confidence: 99%

High-Dose Asian Ginseng (Panax Ginseng) for Cancer-Related Fatigue

et al. 2015

View full text Add to dashboard Cite

Introduction and Objective. Cancer-related fatigue (CRF) is the most common and severe symptom in patients with cancer. The number and efficacy of available treatments for CRF are limited. The objective of this preliminary study was to assess the safety of high-dose Panax ginseng (PG) for CRF. Methods. In this prospective, open-label study, 30 patients with CRF (≥4/10) received high-dose PG at 800 mg orally daily for 29 days. Frequency and type of side effects were determined by the National Cancer Institute’s Common Terminology Criteria for Adverse Events, version 4.0. Scores on the Functional Assessment of Chronic Illness Therapy–Fatigue (FACIT-F) scale, Edmonton Symptom Assessment System (ESAS), and Hospital Anxiety and Depression Scale (HADS) were assessed at baseline, day 15, and day 29. Global Symptom Evaluation (GSE) was assessed at day 29. Results. Of the 30 patients enrolled, 24 (80%) were evaluable. The median age was 58 years; 50% were females, and 84% were white. No severe (≥grade 3) adverse events related to the study drug were reported. Of the 24 evaluable patients, 21 (87%) had an improved (by ≥3 points) FACIT-F score by day 15. The mean ESAS score (standard deviation) for well-being improved from 4.67 (2.04) to 3.50 (2.34) ( P = .01374), and mean score for appetite improved from 4.29 (2.79) to 2.96 (2.46) ( P = .0097). GSE score of PG for fatigue was ≥3 in 15/24 patients (63%) with median improvement of 5. Conclusion. PG is safe and improves CRF fatigue as well as overall quality of life, appetite, and sleep at night. Randomized controlled trials of PG for CRF are justified.

show abstract

“…It is an instrument of easy application and has been used extensively in studies with non-psychiatric clinical populations. 14,15 Data analysis Satiation was summarized as the number of calories (Kcal) ingested until the point of maximum satiation was reached. Postprandial symptoms were summarized by the sum of individual (fullness, nausea, bloating and pain) symptoms scores 30 min after finishing drinking.…”

Section: Eating Attitude Test (Eat-26)mentioning

confidence: 99%

Meal size can be decreased in obese subjects through pharmacological acceleration of gastric emptying (The OBERYTH trial)

Torra

Ilzarbe

Malagelada³

et al. 2010

Int J Obes

View full text Add to dashboard Cite

Background: Entry of nutrients into the small intestine activates neuro-hormonal signals that regulate food intake through induction of satiation. Objective: To evaluate whether caloric intake can be decreased by pharmacologically accelerating gastric emptying (GE) of nutrients into the small intestine. Methods: Subjects were tested in 2 days, at baseline (day1) and after randomly receiving, in a double-blind manner, a 1 h infusion of erythromycin (3 mg Kg À1 , to accelerate GE) or placebo (day 2). Ad libitum caloric intake and postprandial gastrointestinal symptoms were evaluated using a validated nutrient drink test, simultaneously measuring gastric by scintigraphy. Plasma levels of satiation factors were also measured to evaluate their role in the modification of caloric intake and postprandial symptoms. Acceleration of GE was assessed as the difference in percentage emptied between day 2 and day 1 (DGE). The effects of DGE on caloric intake and symptoms were evaluated using multiple (lineal) regression. Results: Among 30 overweight/obese subjects (24F and 6 M), 15 received erythromycin and 15 placebo. The overall median age was 36 years (IQR: 30-42) and body mass index was 30 Kg m À2 (IQR: 27-36). Subjects receiving erythromycin on day 2 presented accelerated GE as compared with placebo (P ¼ 0.0002). DGE at 15 min after initiating eating had a significant effect on prospective caloric intake (P ¼ 0.004). From the best-fitted regression model (R 2 ¼ 81%, Po0.0001), a 10% increase in GE at 15 min induced on an average a 135±43.5 Kcal decrease in caloric intake. Postprandial increase in cholecystokinin (CCK) (P ¼ 0.03) and insulin (P ¼ 0.02) was associated with decreased caloric intake. Acceleration of GE at 60 min after initiating eating increased postprandial symptom scores measured 30 min after the completion of food consumption (P ¼ 0.01). Postprandial increase in CCK (P ¼ 0.002) and PP (P ¼ 0.02) was associated with postprandial symptoms. Conclusion: Meal size can be reduced in overweight/obese subjects by pharmacologically accelerating GE. This may be a reasonable target in obesity management.

show abstract

Construct validation of the hospital anxiety and depression scale with clinical populations

Cited by 308 publications

References 10 publications

Emotional distress in cancer patients: the Edinburgh Cancer Centre symptom study

Emotional distress in cancer patients: the Edinburgh Cancer Centre symptom study

High-Dose Asian Ginseng (Panax Ginseng) for Cancer-Related Fatigue

Meal size can be decreased in obese subjects through pharmacological acceleration of gastric emptying (The OBERYTH trial)

Contact Info

Product

Resources

About